[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Memphis\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":114},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,72,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100540601","examining-the-efficacy-of-a-digital-therapeutic-to-prevent-suicidal-behaviors-100540601",false,"NCT06318962","Examining the Efficacy of a Digital Therapeutic to Prevent Suicidal Behaviors","Inclusion Criteria:\n\n* at least 18 years old\n* suicidal ideation within the past week and\u002For a suicide attempt within the past 30 days\n* ability to complete the informed consent process\n* ownership of either an Apple iPhone iOS 11 or higher or an Android smartphone OS 8.1 or higher\n\nExclusion Criteria:\n\n* an inability to complete informed consent procedures (e.g., acute intoxication, altered consciousness)\n* experiencing active psychosis or mania requiring hospitalization; (3) and inability to use a smartphone.","ALL","18 Years",{"count":18,"type":19},400,"ESTIMATED","INTERVENTIONAL",[22],"NA","The primary aim of the project is to test the efficacy of BCBT delivered via a digital platform (i.e., smartphone) to Servicemembers with recent suicidal ideation and\u002For suicide attempts presenting to primary care clinics. Given existing challenges of scaling empirically-supported treatments\u002Finterventions for suicidality with fidelity, this project could lead to markedly expanded access to BCBT, along with improving our understanding about what intervention strategies are most effective and how they can be delivered with meaningful fidelity. Aviva, the digital version of BCBT, was developed for use with patients across the full spectrum of healthcare settings, including primary care. Aviva is not an emergency alert system, rather a digital platform for delivery of the full scope of BCBT treatment components. An open-label single group Phase I clinical trial has demonstrated the safety, tolerability, feasibility, fidelity, and potential efficacy of Aviva, with participants completing modules over 8 weeks, and follow-up assessments at weeks 1, 4, and 8. Subsequent refinements included the addition of technical features that would allow patients to revisit and\u002For repeat previously completed modules, along with integration of more characters for delivering video vignettes and greater opportunities for skills practice and treatment engagement. These modifications have further enhanced Aviva safety, tolerability, and fidelity, consistent with the original BCBT protocol. Not only is it hypothesized that Aviva will result in significantly larger reductions in severity of suicidal ideation than participants randomized to the control condition, but also that greater app engagement will be negatively correlated with severity of suicidal thinking. Moderators and mediators (i.e. suicidal beliefs, wish to live, impulsive decision-making) of intervention effects will also be examined. The study will be conducted at the primary care clinics at Fort Carson, with a goal of enrolling 720 patients across a two-year timeframe. Participants will be identified using each clinic's existing suicide risk assessment methods, including the PHQ-9 suicide risk item and a score of 1 or higher on the CSSRS Screener (Recent). Participants will be randomly assigned to one of two treatment conditions, Aviva or control (i.e., development of a safety plan consistent with local procedures and policies, along with referral for standard mental health care and suicide risk management in accordance with local policies and procedures). In an effort to address potential performance bias specific to smartphone use, participants in the control condition will download the Suicide Safety Plan app to their smartphones. Those in the Aviva condition will also complete weekly check-ins with Project 2 research clinicians to review treatment adherence, identify and respond to any logistical\u002Foperational problems, and respond to any unexpected emergencies and\u002For participant safety concerns. Participants will have up to five data points: baseline, 3, 6, 9, and 12 months. All data available from all participants and all time points will be included in the analyses, consistent with the intent-to-treat principle. Across our two previous clinical trials and our in-progress RCT, attrition during the first 12 months postbaseline was \\<30% and we anticipate similar rates in this trial.",[25,26,27],"Suicidal Behaviors","Suicide Ideation","Depression\u002FAnxiety",[29,26,30,31],"BCBT","Suicide Attempts","Depression and Anxiety","RECRUITING","2026-05-04",{"date":35,"type":36},"2026-05-05","ACTUAL",{"date":38,"type":36},"2024-02-07",{"date":40,"type":19},"2027-08-01",{"name":42,"class":43},"University of Memphis","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":44},"100631950","beverage-hydration-index-of-different-solutions-100631950","NCT07507344","Beverage Hydration Index of Different Solutions","Comparison of the Beverage Hydration Index of Different Solutions","* Be age 18 years or older\n* male or female\n* have a body mass index (BMI)between 18.5-35 kg\u002Fm2 (not morbidly obese)\n* Be engaged in moderate physical activity, defined as ≤5 hours\u002Fweek of aerobic exercise\n* Not have a history or presence of a clinically relevant (that required or requires treatment) cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, biliary, gastrointestinal, pancreatic, or neurologic disorder (reviewed by Nurse practitioner)\n* Not have other conditions that are likely to alter fluid balance or be negatively affected by changing electrolyte levels\u002Fhydration status (as determined by Nurse practitioner)\n* Not be consuming any medication which may alter fluid retention\u002Felectrolyte levels such as Selective Serotonin Reuptake Inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitor (for type 2 diabetes), laxatives, diuretics, Apremilast, chemotherapy, or lithium. (Medications will be reviewed by Nurse practitioner)\n* Not consume nutritional supplements, performance enhancing drugs, and\u002For non-steroidal anti-inflammatory drugs within 7 days of study visits excluding screening.\n* Follow the lifestyle and dietary restrictions before study visits (excluding screening\u002Fconsenting visit) including before each visit avoiding strenuous activity for 24 hours prior, refrain from caffeine for 12 hours and alcohol for 24 hours, consume the standardized diet and maintain similar activity levels for 24 hours prior, consume 2.5 liters for men or 2.0 liters for women day prior, and fast (water only) of at least 10 hours prior.\n* Not have a sensitivity or be allergic to any components of the study interventions (water, calcium chloride, magnesium chloride, potassium bicarbonate, magnesium, sodium, chloride, potassium, vitamin C, dextrose, AminoAbsorb (L-alanine, L-glutamine, glycine).\n* Not be a tobacco user\n* Not be following a specialized dietary pattern that may alter findings (e.g., low carbohydrate\u002Fketogenic diet, carnivore diet, intermittent fasting etc.)\n* Arrive to lab for visits euhydrated (USG 1.005-1.020)\n* Have the ability and willingness to fast (consume water\u002Ftreatments only) for 15 hours (10 hours prior to lab visits not including screening)\n* Not be enrolled in another clinical study within 30 days of the first study visit\n* Be without active infection or illness of any kind\n* Not be pregnant or breastfeeding\n* Not have surgery in the previous 4 months",true,{"count":54,"type":19},30,[22],"In this study, the impact of two electrolyte hydration stick products (Hydramin containing an electrolyte\u002Famino acid formulation and an identical electrolyte product with the amino-acids replaced with carbohydrate, dextrose) dissolved in 1 liter of water will be assessed and compared to a control (1 liter Smart Water). It is hypothesized that the addition of amino acids and glycine should improve the Beverage Hydration Index above water alone and perform comparably to the carbohydrate rich solution.\n\nThis study will focus on general population (not athletes) and follow very similar approaches used in previous studies within the Center for Nutraceutical and Dietary Supplements Research, with the addition of blood glucose testing and body water measurements. Hydration will be assessed via fluid balance (the difference between the amount of water consumed and passed as urine) and calculations of beverage hydration index (the relative amount of urine passed after consumption of a drink compared to water)as well as time in positive fluid balance, and specific gravity, and sodium and potassium in urine. Blood glucose before and following consumption using finger pricks and a glucometer will also be assessed.",[58],"Hydration",[60,61,62,63],"hydration","electrolytes","Hydramin","Beverage Hydration Index","2026-04-01",{"date":66,"type":36},"2026-04-07",{"date":68,"type":36},"2026-02-23",{"date":70,"type":19},"2026-06-30",{"name":42,"class":43},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100609497","impact-of-the-inno-cleanse-dietary-supplement-on-gut-health-and-associated-variables-in-healthy-men-and-women-100609497","NCT07215351","Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women","Inclusion Criteria:\n\n* experience regular (2 or more days per week) bloating or constipation\n* able to fast a minimum of 12 hours prior to testing visit\n\nExclusion Criteria:\n\n* pregnant, planning to become pregnant, or breastfeeding\n* sensitivity or allergic to any components of the study product (cascara sagrada bark powder, cape aloe leaves extract, senna leaf powder, frangula bark powder fennel seed powder, bentonite clay, burdock root powder, licorice root extract, slippery elm bark powder, Capiscum annuum L. Fruit powder, milk thistle seed powder, hydroxypropyl methylcellulose, cellulose, and silicon dioxide).\n* experienced a severe allergic reaction that resulted in emergency care\n* diagnosed with medical disorders linked to digestive\u002Fgut health such as celiac disease, crohn's disease, gastroesophageal reflux disease, heartburn, irritable bowel syndrome, ulcerative colitis, ulcers, etcetera.\n* experiencing regular diarrhea\n* active infection or illness\n* diabetic\n* hypertensive\n* cardiovascular disease\n* breast, uterine, or ovarian cancer\n* uterine fibroids or endometriosis\n* taking medications or supplements that may alter gut health including but not limited to diuretics, laxatives, anti-diarrheal, anticholinergic agents, or antispasmodic agents.\n* previous adverse experience with laxatives\n* taking medications known to interact with the dietary supplement's ingredients including blood pressure medications, anticoagulants, antiplatelets, blood thinners, cholesterol-lowering medications, diuretics, water pills, estrogen based contraceptives, non-steroidal anti-inflammatory drugs, digoxin, corticosteroids, Monoamine oxidase inhibitors, insulin, medications processed in the liver, diclofenac, fluvastatin, glipizide, ibuprofen, piroxicam, phenytoin, phenobarbital, or secobarbital.\n* tobacco user\n* strenuous activity within 24 hours of testing visits\n* caffeine within 24 hours of testing visit\n* alcohol within 24 hours of testing visit",{"count":54,"type":19},[22],"The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months.\n\nDespite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness.\n\nTherefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.",[82,83],"Constipation","Bloating",[85],"Inno Cleanse",{"date":87,"type":36},"2026-04-02",{"date":89,"type":36},"2025-10-07",{"date":91,"type":19},"2026-05-01",{"name":42,"class":43},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":52,"sex":15,"minAge":16,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":20,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":113,"locationsCount":44},"100548549","information-processing-biases-in-adults-who-stutter-100548549","NCT06422442","Information Processing Biases in Adults Who Stutter","Information Processing Biases in Adults Who Stutter: Behavioral and Eye-tracking Indices of Threat-related Attention Allocation","Inclusion Criteria:\n\n* Speaks English as their primary language\n* Normal hearing (based on pure tone screening)\n* Normal or corrected vision (based on report)\n* Normal color vision (based on Ishihara Test, Concise Edition)\n* Nonverbal intelligence within at least average range based on Test of Nonverbal Intelligence, 4th Edition\n* Expressive language within at least average range score based on Expressive One-Word Picture Vocabulary Test\n\nAdditional inclusion criteria for adults who stutter:\n\n* Self-identification as a person who stutters\n* Score of at least 11 (mild stuttering) on Stuttering Severity Index, 4th Edition\n\nExclusion Criteria:\n\n* Reported significant medical history\n* Psychological or emotional disorder\n* History of frank neurological injury\n* Known speech, language, or learning disorder(s) other than stuttering\n* Reading difficulties\n* Score within clinically significant range for ADHD on Adults ADHD Self-Rating Scale\n* Score within clinically significant range for depression on Beck Depression Inventory\n* Score within clinically significant range for anxiety on State-Trait Anxiety Inventory","65 Years",{"count":102,"type":19},80,[22],"The goal of this clinical trial is to examine whether stuttering is associated with a tendency to attend more quickly or for longer durations to threat-related information in the environment (threat-related attention bias). The main questions it aims to answer are:\n\nDo adults who stutter, relative to adults who do not stutter, attend to threat-related stimuli more than neutral information? Are attentional biases observed across different types of threat or are they specific to threats related to stuttering experiences? Do measures of attention bias explain individual differences in psychological reactions among adults who stutter?",[106],"Stuttering, Adult","2024-05-15",{"date":109,"type":36},"2024-05-21",{"date":111,"type":36},"2023-09-11",{"date":70,"type":19},{"name":42,"class":43},""]